

**Minutes of the April 1, 2016
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical
Services**

Members present

Bill Ladwig; Richard Holm; Dana Darger; Lenny Petrik; Kelley Oehlke; Deb Farver; Mikel Holland

DSS staff present

Mike Jockheck, RPh

Administrative business

The P&T meeting was called to order by D. Darger at 1:00 p.m. The minutes of the December meeting were presented. R. Holm made a motion to approve. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior authorization update and statistics

The committee reviewed the prior authorization (PA) activity for January 2016. There were a total of 2,829 PAs processed in the month of January, with 100% of those requests responded to in less than eight hours. There were 2,262 requests (80%) received electronically and 567 requests (20%) received by fax.

Analysis of the top 15 therapeutic classes

The committee reviewed the top 15 therapeutic classes by total cost of claims from 10/1/2015 – 12/31/2015. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, insulins, and anticonvulsants, misc. The top 15 therapeutic classes make up 37.06% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 19.27% of total claims.

Hydrocodone review

At the December meeting the committee asked for a review of patients taking hydrocodone. Hydrocodone utilization and the top 50 patients were reviewed. R. Holm made a motion to place all hydrocodone combination products on prior authorization except for the following strengths: 5/325, 7.5/325, and 10/325. D. Farver seconded the motion. The motion was approved unanimously. The prior authorization form and criteria will be developed.

PCSK9 second review

The committee reviewed the prior authorization form provided for PCSK9 inhibitors. There was no public comment. R. Holm made a motion to approve the form. B. Ladwig seconded the motion. The motion was approved unanimously.

Lyrice second review

The committee reviewed the prior authorization form provided for Lyrice. There was no public comment. K. Oehlke made a motion to approve the form. B. Ladwig seconded the motion. The motion was approved unanimously.

Otrexup second review

The committee reviewed the prior authorization form provided for Otrexup. There was no public comment. R. Holm made a motion to approve the form. D. Farver seconded the motion. The motion was approved unanimously.

Durlaza second review

The committee reviewed the prior authorization form provided for Durlaza. There was no public comment. D. Farver made a motion to approve the form. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior authorization forms and criteria annual review

The committee reviewed current prior authorization forms and criteria.

Changes made include:

1. Antidepressants form: add Lexapro to list of medications that do not require PA
2. ARB form: add bullet for generic ARB.
3. Harvoni form: add genotypes 4, 5, and 6

A motion was made by D. Farver to accept these changes and to approve all other forms as is. R. Holm seconded the motion. The motion was approved unanimously.

Narcan review

The committee reviewed Narcan nasal spray clinical information. There was no public comment. The committee requested that Narcan nasal spray be reviewed quarterly. The topic was tabled.

Tivorbex review

The committee reviewed Tivorbex clinical information. There was no public comment. A form will be brought to the next meeting for review.

Nucala review

The committee reviewed Nucala clinical information. Ted Sheedy from GSK spoke regarding Nucala. A form will be brought to the next meeting for review.

Varubi review

The committee reviewed Varubi clinical information. There was no public comment. The committee requested that more information be brought to the June meeting, including Emend utilization.

Zurampic review

The committee tabled the review of Zurampic until the June meeting.

The next meeting is scheduled for June 10, 2016. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.